MRPL12

Across TCGA pan-cancer cohorts, MRPL12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRPL12 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MRPL12 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MRPL12 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where MRPL12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.601	0.938	<.001	48	view →
PDAC	DFS	Quartile	II,III,IV	0.888	0.513	.004	34	view →
CCRCC	DFS	Tertile	IV	0.153	0.908	.024	7	view →
LSCC	DFS	Tertile	II,III,IV	0.887	0.661	.011	7	view →
HNSC	DFS	Tertile	III,IV	1.000	0.893	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRPL12–LUAD (OS)

Open the LUAD breakdown →